Assessment of Amphetamine Withdrawal Symptoms of Lisdexamfetamine Dimesylate Treatment for Adults With Binge-Eating Disorder

2020 ◽  
Vol 22 (2) ◽  
Author(s):  
Brigitte Robertson ◽  
James Wu ◽  
Reginald V. Fant ◽  
Sidney H. Schnoll ◽  
Susan L. McElroy
Keyword(s):  
Eating Disorder ◽  
Binge Eating ◽  
Binge Eating Disorder ◽  
Withdrawal Symptoms ◽  
Lisdexamfetamine Dimesylate ◽  
Amphetamine Withdrawal

Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial

2016 ◽  
Vol 31 (5) ◽  
pp. 382-391 ◽  
Author(s):  
Anna I. Guerdjikova ◽  
Nicole Mori ◽  
Thomas J. Blom ◽  
Paul E. Keck ◽  
Stephanie L. Williams ◽  
...  
Keyword(s):  
Eating Disorder ◽  
Binge Eating ◽  
Binge Eating Disorder ◽  
Controlled Trial ◽  
Lisdexamfetamine Dimesylate

scholarly journals The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA

2016 ◽  
Vol 36 (4) ◽  
pp. 305-312 ◽  
Author(s):  
Tamás Ágh ◽  
Manjiri Pawaskar ◽  
Balázs Nagy ◽  
Jean Lachaine ◽  
Zoltán Vokó
Keyword(s):  
Eating Disorder ◽  
Cost Effectiveness ◽  
Binge Eating ◽  
Binge Eating Disorder ◽  
Lisdexamfetamine Dimesylate ◽  
The Usa ◽  
The Cost

scholarly journals A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder

2017 ◽  
Vol 37 (3) ◽  
pp. 315-322 ◽  
Author(s):  
Maria Gasior ◽  
James Hudson ◽  
Javier Quintero ◽  
M. Celeste Ferreira-Cornwell ◽  
Jana Radewonuk ◽  
...  
Keyword(s):  
Eating Disorder ◽  
Binge Eating ◽  
Binge Eating Disorder ◽  
Open Label ◽  
Phase 3 ◽  
Lisdexamfetamine Dimesylate

Overview of the treatment of binge eating disorder

CNS Spectrums ◽  
2015 ◽  
Vol 20 (6) ◽  
pp. 546-556 ◽  
Author(s):  
Susan L. McElroy ◽  
Anna I. Guerdjikova ◽  
Nicole Mori ◽  
Maura R. Munoz ◽  
Paul E. Keck
Keyword(s):  
Weight Loss ◽  
Eating Disorder ◽  
Binge Eating ◽  
Eating Behavior ◽  
Binge Eating Disorder ◽  
Randomized Clinical Trials ◽  
Behavioral Therapy ◽  
Lisdexamfetamine Dimesylate ◽  
Interpersonal Therapy ◽  
Limited Effectiveness

We performed a qualitative review of treatment studies of binge eating disorder (BED), focusing on randomized clinical trials (RCTs). Limited effectiveness has been demonstrated for self-help strategies, and substantial effectiveness has been shown for cognitive behavioral therapy (CBT) and interpersonal therapy (IPT). CBT and IPT may each be more effective than behavior weight loss therapy (BWLT) for reducing binge eating over the long term. The stimulant pro-drug lisdexamfetamine dimesylate (LDX) is the only drug approved by the FDA for the treatment of BED in adults based on 2 pivotal RCTs. Topiramate also decreases binge eating behavior, but its use is limited by its adverse event profile. Antidepressants may be modestly effective over the short term for reducing binge eating behavior and comorbid depressive symptoms, but are not associated with clinically significant weight loss. A RCT presented in abstract form suggests that intranasal naloxone may decrease time spent binge eating. There is no RCT of obesity surgery in BED, but many patients with BED seek and receive such surgery. While some studies suggest patients with BED and obesity do just as well as patients with obesity alone, other studies suggest that patients with BED have more post-operative complications, less weight loss, and more weight regain. This evidence suggests that patients with BED would benefit from receiving highly individualized treatment.

scholarly journals Impulsivity and Its Relationship With Lisdexamfetamine Dimesylate Treatment in Binge Eating Disorder

2021 ◽  
Vol 12 ◽  
Author(s):  
Kristi R. Griffiths ◽  
Leonor Aparício ◽  
Taylor A. Braund ◽  
Jenny Yang ◽  
Grace Harvie ◽  
...  
Keyword(s):  
Eating Disorder ◽  
Binge Eating ◽  
Binge Eating Disorder ◽  
Mixed Models ◽  
Loss Of Control ◽  
Lisdexamfetamine Dimesylate ◽  
Trait Impulsivity ◽  
Normative Comparison ◽  
The Relationship ◽  
Comparison Data

High trait impulsivity is thought to contribute to the sense of loss of control over eating and impulses to binge eat experienced by those with binge eating disorder (BED). Lisdexamfetamine dimesylate (LDX), a drug approved for treatment of moderate to severe BED, has been shown to decrease impulsive features of BED. However, the relationship between LDX-related reductions of binge eating (BE) episodes and impulsivity has not yet been explored. Forty-one adults aged 18–40years with moderate to severe BED completed questionnaires and tasks assessing impulsivity at baseline and after 8weeks of 50–70mg of LDX. Twenty age-matched healthy controls were also assessed at two timepoints for normative comparison. Data were analysed using linear mixed models. BED participants exhibited increased self-reported motor, non-planning, cognitive and food-related impulsivity relative to controls but no differences in objective task-based measures of impulsivity. Food-related and non-planning impulsivity was significantly reduced by LDX, but not to normative levels. Individuals with higher baseline levels of motor and non-planning impulsivity, and loss of control over eating scores experienced the greatest reduction in BE frequency after 8weeks of LDX. Further, there were significant associations between the degree to which subjective loss of control over eating, non-planning impulsivity and BE frequency reduced after 8weeks of LDX. These data suggest that specific subjective measures of impulsivity may be able to predict who will have the greatest benefit from LDX treatment and that reductions in BE frequency may be moderated by concurrent reductions in non-planning impulsivity.

Sign in / Sign up

Export Citation Format

Share Document